HT 100, an anti-inflammatory compound discovered by Mark Pines at the Volcani Institute, will be further developed by Processa Pharmaceuticals.
Processa Pharmaceuticals Will Evaluate HT-100 as Treatment for IPF, Other Fibrotic Diseases
top of page
bottom of page